Co-transduction of herpes simplex virus thymidine kinase gene and human interleukin-2 gene into mouse ovarian cancer cell line, OVHM.

  • Authors:
    • Y Yamaguchi
    • I Takashima
    • J Hihara
    • K Ohta
    • K Shimizu
    • K Minami
    • K Yoshida
    • T Toge
  • View Affiliations

  • Published online on: August 1, 2000     https://doi.org/10.3892/ijmm.6.2.185
  • Pages: 185-275
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We studied the thymidine kinase (TK) gene and the interleukin (IL)-2 gene co-transduction into tumor cells for a possible strategy of cancer gene therapy. A murine ovarian cancer cell line, OVHM, was retrovirally transduced with the TK (OVHM/TK) or the IL-2 gene (OVHM/IL-2). The TK or IL-2 expression was permanent in OVHM/TK or OVHM/IL-2. OVHM/TK cells were susceptible to gancyclovir (GCV) in vitro, and their intraperitoneal growth was completely regulated with GCV administration. The bystander effect was not observed in vitro and in vivo in this model, and only the marginal emergence of immune involvement was observed in the OVHM/TK-cured mice with GCV. OVHM/IL-2 cells produced IL-2 biologically active to be immunogenic, but still tumorigenic to kill the mice when inoculated intraperitoneally. Then, OVHM/TK cells were co-transduced with the IL-2 gene to establish OVHM/TK/IL-2 cells. OVHM/TK/IL-2 cells were also susceptible to GCV and transiently produced active IL-2. A significant resistance against the challenge of parental tumor cells was observed in the mice that were inoculated with OVHM/TK/IL-2 cells and cured with GCV administration. It is suggested that tumor cells transduced with both TK and IL-2 genes could be regressed with GCV administration with subsequent generation of immune activation in the host. Since the bystander effect may not always be a common phenomenon in gene therapy using the TK gene, this type of combination may be advantageous in the clinical application of gene therapy for human cancers.

Related Articles

Journal Cover

Aug 2000
Volume 6 Issue 2

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yamaguchi Y, Takashima I, Hihara J, Ohta K, Shimizu K, Minami K, Yoshida K and Toge T: Co-transduction of herpes simplex virus thymidine kinase gene and human interleukin-2 gene into mouse ovarian cancer cell line, OVHM.. Int J Mol Med 6: 185-275, 2000
APA
Yamaguchi, Y., Takashima, I., Hihara, J., Ohta, K., Shimizu, K., Minami, K. ... Toge, T. (2000). Co-transduction of herpes simplex virus thymidine kinase gene and human interleukin-2 gene into mouse ovarian cancer cell line, OVHM.. International Journal of Molecular Medicine, 6, 185-275. https://doi.org/10.3892/ijmm.6.2.185
MLA
Yamaguchi, Y., Takashima, I., Hihara, J., Ohta, K., Shimizu, K., Minami, K., Yoshida, K., Toge, T."Co-transduction of herpes simplex virus thymidine kinase gene and human interleukin-2 gene into mouse ovarian cancer cell line, OVHM.". International Journal of Molecular Medicine 6.2 (2000): 185-275.
Chicago
Yamaguchi, Y., Takashima, I., Hihara, J., Ohta, K., Shimizu, K., Minami, K., Yoshida, K., Toge, T."Co-transduction of herpes simplex virus thymidine kinase gene and human interleukin-2 gene into mouse ovarian cancer cell line, OVHM.". International Journal of Molecular Medicine 6, no. 2 (2000): 185-275. https://doi.org/10.3892/ijmm.6.2.185